9 Jan

Analysts’ Recommendations for Mylan

WRITTEN BY Kenneth Smith

Company overview

Mylan (MYL), which has a global presence, is focused on developing, manufacturing, and distributing generic, brand name, and over-the-counter products in various therapeutic categories. Mylan operates a vertically integrated manufacturing platform. According to the company, its product portfolio comprises more than 7,500 marketed products commercialized in more than 165 countries.

Analysts’ Recommendations for Mylan

Analysts’ ratings

Of the 22 analysts covering Mylan in December 2017, 14 assigned it a “buy” or higher rating, and eight recommended “hold.” The mean rating for the stock is 2.1, and its mean target price is $44.10. Notably, Mylan makes up about 1.0% of the First Trust NASDAQ-100 Equal Weighted Index ETF (QQEW).

Peer ratings

In December 2017, of the 24 analysts covering Pfizer (PFE) in December 2017, 13 assigned it a “buy” or higher rating, and nine recommended “hold.” The mean rating for the stock is 2.5, and its mean target price is $38.29. Of the 23 analysts covering Merck (MRK), 13 assigned it a “buy” or higher rating, and ten recommended “hold.” The mean rating for the stock is 2.1, and its mean target price is $65.23. Of the 24 analysts covering Bristol-Myers Squibb (BMY), ten assigned it a “buy” or higher rating, and 12 recommended “hold.” The mean rating for the stock is 2.4, and its mean target price is $63.86. In the next part of this series, we’ll look at Mylan’s product portfolio.

Latest articles

Investors have been holding their breath for a Fed rate cut for a while now. But are they prepared in the event that that doesn't happen?

Innovative Industrial Properties (IIPR) continued to slump on July 22. The stock lost almost 6.8% of its value on the day.

22 Jul

Why AT&T Stock Is Down 2.2% Today

WRITTEN BY Ambrish Shah

AT&T stock (T) was trading at $32.14 with a 2.0% loss for the day. Earlier today, it posted a low of $32.08. Is the stock overvalued right now?

The Walt Disney Company’s (DIS) superhero film Avengers: Endgame has finally surpassed the record set by James Cameron’s Avatar.

22 Jul

Why Durect Corporation Is Soaring Today

WRITTEN BY Margaret Patrick

On July 22, Durect Corporation (DRRX) entered into a collaboration with HIV leader Gilead Sciences (GILD).

Pure Alpha, the flagship fund of Ray Dalio’s Bridgewater Associates, fell 4.9% in the first half, the Financial Times reported.